Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 95 of 6351
-
Gene therapy aims to restore sight in rare blindness condition
Disease control OngoingThe objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 12 years old and ≤ 75 years old to receive a single bilateral intravitreal (IVT) injecti…
Phase 3 • Sponsor: Wuhan Neurophth Biotechnology Limited Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can a smallpox vaccine stop mpox in its tracks?
Prevention OngoingA cluster randomized controlled trial to determine if smallpox vaccine reduces secondary cases and symptom severity in persons exposed to mpox.
Phase 4 • Sponsor: McMaster University • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
New mRNA flu shot shows promise in large trial for older adults
Vaccine CompletedThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined in…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 26, 2026 16:46 UTC
-
AI reads heart rhythms to unmask silent heart disease
Diagnosis Recruiting nowThe goal of this clinical trial is to determine if a machine learning/artificial intelligence (AI)-based electrocardiogram (ECG) algorithm (rECHOmmend and ECG-AF) can identify undiagnosed cardiovascular disease in patients. It will also examine the safety and effectiveness of usi…
Sponsor: Northwestern University • Aim: Diagnosis
Last updated Aug 22, 2026 00:00 UTC
-
Triple threat before surgery: new combo aims to crush lung cancer
Disease control Recruiting nowThis is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.
Phase 3 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentia…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
CRISPR gene therapy aims to fix hemophilia b at the DNA level
Disease control Recruiting nowParticipants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called RE…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Pap test DNA may spot ovarian cancer years before symptoms
Diagnosis Recruiting nowOvarian cancer is the leading cause of death among gynecological malignancies. No screening test is available for this tumor. Serous Tubal Intraepithelial Carcinoma (STIC) is the precursor lesion of the high grade serous ovarian cancer (HGSOC). Preliminary data suggest that tumor…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Can a new antiplatelet drug outperform clopidogrel after a heart attack?
Disease control Recruiting nowThis is a multi-center, randomized, double-blind, double-dummy, parallel-controled, phase III trial, aiming to evaluate the effectiveness and safety of long-term continuous administration of Vicagrel capsules in ACS patients undergoing PCI.
Phase 3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can reprogrammed immune cells take on hard-to-treat kidney cancer?
Cure PausedThis is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Wearable bracelet could alert stroke patients within 3 hours
Diagnosis Recruiting nowThe aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset. This is a multicenter, prospective observational single-arm trial with a registry-based propen…
Sponsor: Region Skane • Aim: Diagnosis
Last updated Jul 02, 2026 00:00 UTC
-
One-Time cell therapy could tame tough lupus
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take on tough leukemias
Disease control Recruiting nowBackground: Chronic lymphocytic leukemia (CLL),small lymphocytic lymphoma (SLL) and B-cell acute lymphoblastic leukemia or lymphoma (ALL) are blood cancers that affect certain white blood cells. Advanced forms of these diseases are difficult to treat. CD19 is a protein often fou…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a new valve device fix a leaky heart without open surgery?
Disease control Recruiting nowThis is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Sponsor: 4C Medical Technologies, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises
Disease control Recruiting nowThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can immunotherapy plus hormones spare the womb in early endometrial cancer?
Disease control Recruiting nowThe objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Landmark trial aims to find best cure for early Voice-Box cancer
Cure Recruiting nowThis randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR…
Sponsor: Viktoras Rudzianskas • Aim: Cure
Last updated Jun 27, 2026 09:02 UTC
-
New drug combo aims to protect kidneys and heart in 11,000-Patient trial
Disease control Recruiting nowThis study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin recepto…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowA Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis
Phase 2/3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowResearchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC means lung cancer that has spread nearby or to other parts …
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC